Search Result

Results for "

G-12

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (1) Adhesion G Protein-coupled Receptors (AGPCRs) (1) Akt (9) AMPK (1) Amyloid-β (1) Apoptosis (29) Autophagy (2) Bcl-2 Family (3) Bombesin Receptor (1) c-Fms (1) Caspase (6) CDK (1) Cuproptosis (1) Drug Derivative (1) Drug Intermediate (6) Drug Isomer (3) E3 Ligase Ligand-Linker Conjugates (3) EGFR (1) ERK (30) Fluorescent Dye (1) HIV (1) IFNAR (5) Interleukin Related (1) Isotope-Labeled Compounds (7) JNK (1) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (4) LYTACs (1) MEK (4) Mitochondrial Metabolism (2) MMP (1) Molecular Glues (1) mTOR (4) NF-κB (1) Nucleoside Antimetabolite/Analog (1) p38 MAPK (9) PARP (4) PD-1/PD-L1 (1) PERK (14) Phosphatase (1) PI3K (8) PKA (2) Potassium Channel (1) PROTACs (21) Protease Activated Receptor (PAR) (1) Proton Pump (1) Raf (5) Ras (293) Reactive Oxygen Species (ROS) (3) Reference Standards (1) RET (1) Ribosomal S6 Kinase (RSK) (1) SARS-CoV (1) Small Interfering RNA (siRNA) (4) SOS1 (15) Target Protein Ligand-Linker Conjugates (3) TNF Receptor (3) Trk Receptor (1) ULK (1) VEGFR (1) Virus Protease (1) Wnt (1) YAP (1) β-catenin (1)
By Research Areas:	Cancer (329) Endocrinology (1) Infection (2) Inflammation/Immunology (10) Metabolic Disease (2) Neurological Disease (1)
Click Chemistry:	Azide (3) Alkynes (28)
Oligonucleotides:	Guanosine (1) Nucleoside Analogs (1) Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (2) siRNAs (4)

345

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-176523

*KRAS G12D-IN-29*	Ras	Cancer
KRAS G12D inhibitor 29 (Compound Formula (I)) is an orally active and selective KRAS ^G12D mutant inhibitor. KRAS G12D inhibitor 29 blocks downstream signaling pathways mediated by KRAS ^G12D, suppressing tumor cell proliferation. KRAS G12D inhibitor 29 is promising for research of KRAS ^G12D mutation-related cancers (such as pancreatic cancer, lung cancer, colorectal cancer) .

HY-139186

*PROTAC KRAS G12C degrader-1*	PROTACs Ras	Cancer
PROTAC KRAS G12C degrader-1 is a Cereblon-based KRAS ^G12C PROTAC degrader. PROTAC KRAS G12C degrader-1 induces CRBN/ KRAS ^G12C dimerization and degrades GFP- KRAS ^G12C in reporter cells .

HY-164315

*KRAS G12C inhibitor 67*	Ras PERK	Cancer
KRAS G12C inhibitor 67 (Example 35) is an orally active KRAS G12C inhibitor. KRAS G12C inhibitor 67 inhibits pERK and active KRas. KRAS G12C inhibitor 67 selectively inhibits the growth of various KRAS G12C mutant tumor cell lines. KRAS G12C inhibitor 67 exhibits anticancer activity against esophageal cancer, bladder cancer, colorectal cancer, lung cancer, and pancreatic cancer .

HY-161176

*PROTAC KRAS G12D degrader 1*	PROTACs Ras ERK	Cancer
PROTAC KRAS G12D degrader 1 is a selective PROTAC KRAS ^G12D degrader. PROTAC KRAS G12D degrader 1 inhibits proliferation of KRAS ^G12D-mutant cells and suppresses ERK phosphorylation. PROTAC KRAS G12D degrader 1 inhibits tumor growth in mice bearing AsPC-1 xenografts. PROTAC KRAS G12D degrader 1 can be used for the study of KRAS ^G12D-driven cancers.(Pink: KRAS ligand (HY-175892), Blue: VHL Ligand (HY-112078), Black: Linker, E3 ligase ligand-linker conjugate (HY-175893)) .

HY-144661

*KRAS G12D inhibitor 14*	Ras Apoptosis	Cancer
KRAS G12D inhibitor 14 is a potent KRAS G12D inhibitor with a K_D of 33 nM for binding to KRAS G12D protein. KRAS G12D inhibitor 14 decreases the active form of KRAS G12D (KRAS G12D-GTP) but not KRAS G13D .

HY-158008

*(R)-G12Di-7*	Ras	Cancer
(R)-G12Di-7 is a covalent ligand for *KRAS-G12D, which selectively labels K-Ras-G12D·GDP* and K-Ras-G12D·GppNHp. (R)-G12Di-7 exhibits inhibitory activity against G12D mutated cancer cells .

HY-151523

*KRas G12R inhibitor 1*	Ras	Cancer
KRas G12R inhibitor 1 is a covalent inhibitor targeting the common oncogenic mutant KRas G12R with selectivity for the mutant arginine. KRas G12R inhibitor 1 possesses an α,β-diketoamide and exploits strong nucleophilicity of the mutant cysteine and irreversibly binds in the Switch II region of KRas. KRas G12R inhibitor 1 can be researched for K-Ras (G12R)-driven cancer such as pancreatic ductal adenocarcinoma (PDAC) .

HY-P99611

Faralimomab 64G12	IFNAR	Inflammation/Immunology
Faralimomab (64G12) is an immunomodulator, and a murine anti-IFNA1 IgG1 mAb .

HY-171255

*KRAS G12D inhibitor 26*	Ras	Cancer
KRAS G12D inhibitor 26 is a modulator of Kras, targeting Kras(G12D) with an IC₅₀ ≤ 100 nM .

HY-177511

*KRAS G12D-IN-30*	Ras p38 MAPK Raf MEK ERK	Cancer
KRAS G12D-IN-30 (Compound 4) is a KRAS inhibitor. KRAS G12D-IN-30 inhibits the activation of the downstream MAPK signaling cascade (Raf1-MEK-ERK) by blocking the activity of the KRAS G12 mutant. KRAS G12D-IN-30 can be used for the research of cancer .

HY-139911

*KRAS G12D inhibitor 7*	Ras	Cancer
KRAS G12D inhibitor 7 is an inhibitor of KRAS G12D. KRAS G12D inhibitor 7 can be used for the research of cancer .

HY-P5192

*KRAS G12D(8-16)*	Ras	Cancer
KRAS G12D 8-16 is a mutant KRAS G12D 8-16 peptide .

HY-153413

*Kras4B G12D-IN-1*	Ras	Cancer
Kras4B G12D-IN-1 is a Kras4B G12D inhibitor with anticancer effects. Kras4B G12D-IN-1 decreases Kras protein expression in mouse embryonic fibroblasts (MEF) expressing Kras4B G12D (WO2016179558A1, Comp 994566) .

HY-143603

*KRAS G12D inhibitor 10*	Ras	Cancer
KRAS G12D inhibitor 10 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 10 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 34) .

HY-143607

*KRAS G12D inhibitor 13*	Ras	Cancer
KRAS G12D inhibitor 13 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 13 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 142) .

HY-172626

*KRAS G12D inhibitor 28*	Ras	Cancer
KRAS G12D inhibitor 28 (Compound 1) is a KRAS G12D inhibitor. KRAS G12D inhibitor 28 (Compound 1) can be used in the cancer research .

HY-125872

*KRAS G12C inhibitor 14*	Ras	Cancer
KRas G12C inhibitor 14 (Compound 17) is a potent KRAS G12C inhibitor (IC₅₀ = 18 nM).

HY-P2360

*G12* Ras 5-17	Ras	Others
G12 (Ras 5-17) is a wild-type Ras peptide consisted of amino acids 5-17 (KLVVVGAGGVGKS). G12 can be used as a control of mutant Ras peptides studies (such V12) .

HY-P11356

*KRAS G12V Peptide*	IFNAR	Cancer
KRAS G12V Peptide is a specific peptide derived from the Kirsten rat sarcoma virus (KRAS) gene carrying the G12V oncogenic mutation. KRAS G12V Peptide induces responses like IFN-γ secretion and cytotoxicity. KRAS G12V Peptide can be used for the study of immune responses against KRAS G12V-mutant tumors .

HY-179414

*KRAS G12D-IN-34*	Ras	Cancer
KRAS G12D-IN-34 (Compound 13) is a KRAS (G12D) inhibitor with IC₅₀ values for KRAS (G12D) and KRAS (WT) of 1.05 nM and 1.59 μM respectively. KRAS G12D-IN-34 can be used for research on non-small cell lung cancer .

HY-P11357A

*KRAS G12C Peptide TFA*	IFNAR	Cancer
KRAS G12C Peptide TFA is the trifluoroacetate salt of KRAS G12C Peptide (HY-P11357). KRAS G12C Peptide is a specific peptide derived from the Kirsten rat sarcoma virus (KRAS) gene carrying the G12C oncogenic mutation. KRAS G12C Peptide induces responses like IFN-γ secretion and cytotoxicity. KRAS G12C Peptide can be used for the study of immune responses against KRAS G12C-mutant tumors .

HY-P11356A

*KRAS G12V Peptide TFA*	IFNAR	Cancer
KRAS G12V Peptide TFA is the trifluoroacetate salt of KRAS G12V Peptide (HY-P11355). KRAS G12V Peptide is a specific peptide derived from the Kirsten rat sarcoma virus (KRAS) gene carrying the G12V oncogenic mutation. KRAS G12V Peptide induces responses like IFN-γ secretion and cytotoxicity. KRAS G12V Peptide can be used for the study of immune responses against KRAS G12V-mutant tumors .

HY-128771

*K-Ras G12C-IN-4*	Ras	Cancer
K-Ras G12C-IN-4, compound 1, is a potent Covalent Inhibitor of KRAS ^G12C .

HY-134811

*KRAS G12D inhibitor 1*	Ras PERK	Cancer
KRAS G12D inhibitor 1 is a KRAS ^G12D inhibitor with an IC₅₀ value of 0.4 nM. KRAS G12D inhibitor 1 inhibits KRas ^G12D-mediated ERK phosphorylation. KRAS G12D inhibitor 1 can be used for cancer research .

HY-143592

*KRAS G12C inhibitor 39*	Ras	Cancer
KRAS G12C inhibitor 39 is a potent inhibitor of KRAS G12C. KRas is a highly attractable target of the pharmaceutical industry for cancer research. KRAS G12C inhibitor 39 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2019099524A1, compound 494) .

HY-P5358

YFLLRNP	Protease Activated Receptor (PAR)	Others
YFLLRNP is a biological active peptide. (a partial agonist of PAR-1. YFLLRNP selectively active G12/13 signaling pathway without activating Gq or Gi pathways at low concentrations. YFLLRNP (60 μM))

HY-143606

*KRAS G12D inhibitor 12*	Ras	Cancer
KRAS G12D inhibitor 12 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 12 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 134) .

HY-143604

*KRAS G12D inhibitor 11*	Ras	Cancer
KRAS G12D inhibitor 11 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 11 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 52) .

HY-143599

*KRAS G12D inhibitor 8*	Ras	Cancer
KRAS G12D inhibitor 8 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 8 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021107160A1, compound 2) .

HY-139894

*KRAS G12D inhibitor 5*	Ras	Cancer
KRAS G12D inhibitor 5 is a KRAS G12D inhibitor for the potential research of pancreatic cancer.

HY-172626A

*(R)-KRAS G12D inhibitor 28 hydrochloride dihydrate*	Ras	Cancer
(R)-KRAS G12D inhibitor 28 hydrochloride dehydrate is the hydrochloride dehydrate of (R)-KRAS G12D inhibitor 28 (HY-172626). KRAS G12D inhibitor 28 (Compound 2) is a KRAS G12D inhibitor. KRAS G12D inhibitor 28 (Compound 2) can be used in the cancer research .

HY-115880

*KRAS G12D inhibitor 3*	Ras	Cancer
KRAS G12D inhibitor 3 is a KRAS G12D inhibitor with an IC₅₀ of <500 nM. KRAS G12D inhibitor 3 has antitumor effects (WO2022002102A1; compound 146) . KRAS G12D inhibitor 3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P2360A

G12 TFA Ras 5-17 TFA	Ras	Others
G12 (Ras 5-17) TFA is a wild-type Ras peptide consisted of amino acids 5-17 (KLVVVGAGGVGKS). G12 TFA can be used as a control of mutant Ras peptides studies (such V12) .

HY-163595

*KRAS G12D-IN-31*	Ras	Cancer
KRAS G12D-IN-31 is a potent KRAS G12D inhibitor with an IC₅₀ of < 100 nM. KRAS G12D-IN-31 inhibits the proliferation of RAS-dependent cells (KRAS ^G12C, KRAS ^G12D, KRAS ^G12V and KRAS ^WT). KRAS G12D-IN-31 can be used to study non-small cell lung cancer, gastric cancer, colon cancer, and malignant melanoma .

HY-P11357

*KRAS G12C Peptide*	IFNAR	Cancer
KRAS G12C Peptide is a specific peptide derived from the Kirsten rat sarcoma virus (KRAS) gene carrying the G12C oncogenic mutation. KRAS G12C Peptide induces responses like IFN-γ secretion and cytotoxicity. KRAS G12C Peptide can be used for the study of immune responses against KRAS G12C-mutant tumors .

HY-18606

*K-Ras G12C-IN-3*	Ras	Cancer
K-Ras G12C-IN-3 (Compound VI-5) is an irreversible small molecule inhibitor of mutant K-Ras G12C. K-Ras G12C-IN-3 can be used in the research of cancers .

HY-158007

*(RS)-G12Di-1*	Ras	Cancer
(RS)-G12Di-1 is a selective, covalent inhibitor of *K-Ras-G12D* .

HY-18604

*K-Ras G12C-IN-1* 1 Publications Verification	Ras	Cancer
K-Ras G12C-IN-1 is a novel and irreversible inhibitor of mutant K-ras G12C extracted from patent WO 2014152588 A1.

HY-153881

*KRAS G12C degrader-1*	Ras	Cancer
KRAS G12C degrader-1 (Compound 283) is a potent KRAS G12C degrader (DC₅₀: < 100 nM) for cancer research. KRAS G12C degrader-1 is a chaperone (HSP90)-mediated protein degrader (CHAMPs) .

HY-160445

*KRAS G12D inhibitor 19*	Ras	Cancer
KRAS G12D inhibitor 19 (Compound 7) is a KRAS G12D inhibitor. KRAS G12D inhibitor 19 can be used for the research of cancer .

HY-162366

*KRAS G12D inhibitor 20*	Ras	Cancer
KRAS G12D inhibitor 20 (Compound 14) is a selective G12D KRAS inhibitor. KRAS G12D inhibitor 20 has antitumor activity .

HY-148260

*KRAS G12D inhibitor 16*	Ras	Cancer
KRAS G12D inhibitor 16 is a KRAS G12D inhibitor. KRAS G12D inhibitor 16 has inhibitory activity against KRAS G12D and KRAS G12D mutation with IC₅₀ value of 0.7 nM and 0.35 μM, respectively. KRAS G12D inhibitor 16 can be used for the research of many malignant tumor, such as pancreatic ductal adenocarcinomas (PDAC), colon and rectal carcinomas (CRC), non-small cell lung carcinomas (NSCLC) .

HY-142460

*KRAS G12C inhibitor 28*	Ras	Cancer
KRAS G12C inhibitor 28 is a KRAS G12C inhibitor with an IC₅₀ of 57 nM. KRAS G12C inhibitor 28 has antitumor effects (WO2021113595A1; Example 1) .

HY-158703

*KRAS G12D inhibitor 24*	Ras	Cancer
KRAS G12D inhibitor 24 (compound 103) is a potent inhibitor of KRAS G12D, with the IC₅₀ of 0.004 μM. KRAS G12D inhibitor 24 has oral bioactivity .

HY-147636

*KRAS G12C inhibitor 55*	Ras	Cancer
KRAS G12C inhibitor 55 (Compound 1) is a KRAS G12C inhibitor .

HY-158701

*KRAS G12D inhibitor 23*	Ras	Cancer
KRAS G12D inhibitor 23 (compound 46-3) is a potent inhibitor of KRAS G12D, with the IC₅₀ of 0.007 μM. KRAS G12D inhibitor 23 plays an important role in cancer research .

HY-142946

*KRAS G12C inhibitor 44*	Ras	Cancer
KRAS G12C inhibitor 44 (compound 54) is a potent and orally active KRAS G12C inhibitor. KRAS G12C inhibitor 44 shows anti-proliferation activities with IC₅₀s of 0.016, 0.028 µM in MIA PaCA-2, H358 cells, respectively. KRAS G12C inhibitor 44 shows antitumor effects in vivo .

HY-112494

*KRas G12C inhibitor 4*	Ras	Cancer
KRas G12C inhibitor 1 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1.

HY-150927

G12Si-2	Ras	Cancer
G12Si-2, an analog of G12Si-1 (HY-150926), is a negative control tool. G12Si-2 is not a covalent inhibitor of the G12S mutant of K-Ras .

HY-174851

*KRAS G12C-IN-70*	Ras	Cancer
KRAS G12C-IN-70 is a selective *KRAS G12C mutant* inhibitor. KRAS G12C-IN-70 blocks KRAS G12C-mediated downstream signaling pathways (e.g., RAF-MEK-ERK) and inhibits tumor cell proliferation. KRAS G12C-IN-70 is promising for research of KRAS G12C mutation-related tumors (such as non-small cell lung cancer, colorectal cancer) .

Cat. No.	Product Name	Target	Research Area

HY-P2265A

SAH-SOS1A TFA	SOS1 Ras	Cancer
SAH-SOS1A TFA is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A TFA binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM). SAH-SOS1A TFA directly and independently blocks nucleotide association. SAH-SOS1A TFA impairs KRAS-driven cancer cell viability and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS .

HY-P11294

KLVVVGADGVGKSALTI	Ras	Cancer
KLVVVGADGVGKSALTI is a KRAS G12D targeting peptide that can be used in tumor research .

HY-P3487

GAGGVGKSA	Peptides	Inflammation/Immunology Cancer
GAGGVGKSA is a wild type *KRAS G12D 9mer* peptide. GAGGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research .

HY-103544

[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P	JNK Interleukin Related Bombesin Receptor	Inflammation/Immunology Cancer
[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P, a Substance P derivative, is a biased agonist toward neuropeptide and chemokine receptors. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P activates *G12. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P binds to IL-8* and GRP receptors. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P inhibits ERK-2 activation, activates JNK activity. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P stimulates an increase in neutrophil migration and Ca ²⁺ mobilization. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P is also a bombesin antagonist, and inhibits the growth of small cell lung cancer

HY-P5192

*KRAS G12D(8-16)*	Ras	Cancer
KRAS G12D 8-16 is a mutant KRAS G12D 8-16 peptide .

HY-P10365

VPM-p15	Adhesion G Protein-coupled Receptors (AGPCRs)	Others
Vmm-p15 is a peptide agonist optimized for the adhesion G protein-coupled receptor GPR64 (also known as ADGRG2 or HE6). The affinity of VPM-p15 with GPR64 is significantly higher than that of the original p15 peptide. The cAMP level induced by VMM-P15 increased significantly, activated GPR64, and triggered downstream Gs, Gq, and G12/13 signaling. VPM-p15 can be used to study the activation mechanism of adherent GPCR family members .

HY-P2360

*G12* Ras 5-17	Ras	Others
G12 (Ras 5-17) is a wild-type Ras peptide consisted of amino acids 5-17 (KLVVVGAGGVGKS). G12 can be used as a control of mutant Ras peptides studies (such V12) .

HY-P3488

GADGVGKSA	Peptides	Inflammation/Immunology Cancer
GADGVGKSA is a mutant *KRAS G12D 9mer* peptide. GADGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research .

HY-P11356

*KRAS G12V Peptide*	IFNAR	Cancer
KRAS G12V Peptide is a specific peptide derived from the Kirsten rat sarcoma virus (KRAS) gene carrying the G12V oncogenic mutation. KRAS G12V Peptide induces responses like IFN-γ secretion and cytotoxicity. KRAS G12V Peptide can be used for the study of immune responses against KRAS G12V-mutant tumors .

HY-P11357A

*KRAS G12C Peptide TFA*	IFNAR	Cancer
KRAS G12C Peptide TFA is the trifluoroacetate salt of KRAS G12C Peptide (HY-P11357). KRAS G12C Peptide is a specific peptide derived from the Kirsten rat sarcoma virus (KRAS) gene carrying the G12C oncogenic mutation. KRAS G12C Peptide induces responses like IFN-γ secretion and cytotoxicity. KRAS G12C Peptide can be used for the study of immune responses against KRAS G12C-mutant tumors .

HY-P11356A

*KRAS G12V Peptide TFA*	IFNAR	Cancer
KRAS G12V Peptide TFA is the trifluoroacetate salt of KRAS G12V Peptide (HY-P11355). KRAS G12V Peptide is a specific peptide derived from the Kirsten rat sarcoma virus (KRAS) gene carrying the G12V oncogenic mutation. KRAS G12V Peptide induces responses like IFN-γ secretion and cytotoxicity. KRAS G12V Peptide can be used for the study of immune responses against KRAS G12V-mutant tumors .

HY-P5358

YFLLRNP	Protease Activated Receptor (PAR)	Others
YFLLRNP is a biological active peptide. (a partial agonist of PAR-1. YFLLRNP selectively active G12/13 signaling pathway without activating Gq or Gi pathways at low concentrations. YFLLRNP (60 μM))

HY-P2360A

G12 TFA Ras 5-17 TFA	Ras	Others
G12 (Ras 5-17) TFA is a wild-type Ras peptide consisted of amino acids 5-17 (KLVVVGAGGVGKS). G12 TFA can be used as a control of mutant Ras peptides studies (such V12) .

HY-P2265

SAH-SOS1A	SOS1 Ras	Cancer
SAH-SOS1A is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM), directly and independently blocks nucleotide association, impairs KRAS-driven cancer cell viability, and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS .

HY-P3486

GADGVGKSAL	Peptides	Inflammation/Immunology Cancer
GADGVGKSAL is a mutant *KRAS G12D 10mer* peptide. GADGVGKSAL can be used as an immunogenic neoantigen for cancer immunotherapy research .

HY-P10847

KS-58	Ras	Cancer
KS-58 is a KRpep-2d (HY-P3277) derivative. KS-58 is a K-Ras (G12D) inhibitory peptide that selectively binds K-Ras. KS-58 can enter cells and block intracellular Ras interaction with effector proteins. KS-58 inhibits the proliferation of tumor cells and has antitumor activity .

HY-P11357

*KRAS G12C Peptide*	IFNAR	Cancer
KRAS G12C Peptide is a specific peptide derived from the Kirsten rat sarcoma virus (KRAS) gene carrying the G12C oncogenic mutation. KRAS G12C Peptide induces responses like IFN-γ secretion and cytotoxicity. KRAS G12C Peptide can be used for the study of immune responses against KRAS G12C-mutant tumors .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990169

Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12)	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse/human phosphorylated PD-1/CD279. Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) can detect the phosphorylated form of the PD-1 ITSM by both western blot and flow cytometry .

HY-P99611

Faralimomab 64G12	IFNAR	Inflammation/Immunology
Faralimomab (64G12) is an immunomodulator, and a murine anti-IFNA1 IgG1 mAb .

HY-P990633

NC-318 (5G-12) 5G-12	Inhibitory Antibodies	Inflammation/Immunology
NC-318 (5G-12) is a human-derived antibody expressed by CHO, targeting Siglec-15/CD33L3. NC-318 (5G-12) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.98 kDa. The isotype control for NC-318 (5G-12) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-125847

Salvianolic acid F 1 Publications Verification	Stilbenes Classification of Application Fields Labiatae Samanea saman (Jacq.) Merr. Phenols Polyphenols Plants Disease Research Fields Source Classification Cancer	Ras PI3K Akt Caspase Apoptosis Bcl-2 Family NF-κB MMP
Salvianolic acid F is a KRAS inhibitor, especially for KRAS G12D. Salvianolic acid F inhibits NF-kB, MMP-9, and NO simultaneously. Salvianolic acid F inhibits cancer cell growth, invasion, and migration and induces apoptosis via the EP300/PI3K/AKT pathway in vitro. Salvianolic acid F inhibits the growth of KRAS-dependent lung cancer cells via the PI3K/AKT signaling pathway in vivo. Salvianolic acid F can be used in the research of various cancers, including KRAS G12D-driven non-small cell lung cancer (NSCLC) and ovarian cancer .

Cat. No.	Product Name	Chemical Structure

HY-176785S

MCB-294

MCB-294 is a dual-state pan-KRAS inhibitor that selectively inhibits KRAS over NRAS and HRAS. MCB-294 capable of binding both the active (GTP-bound) and inactive (GDP-bound) forms of KRAS with K_ds of approximately 1 pM and 10 nM, respectively. MCB-294 broadly impairs the growth of hTERT-HPNE cells expressing G12D, G12C, G12V, G12S, G13D, and wild-type KRAS, with IC₅₀s of approximately 700 nM. MCB-294 induces irreversible apoptosis in KRAS-mutated tumors. MCB-294 effectively suppress KRAS ^G12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-294 can be used for the study of pancreatic cancer, colorectal cancer and lung cancer .

HY-114277S

Sotorasib-d7

Sotorasib-d₇ (AMG-510-d₇) is a deuterium-labeled Sotorasib (HY-114277). Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib leads to the regression of KRAS G12C‑mutated locally advanced or metastatic non‑small cell lung cancer (NSCLC) .

HY-179253

KRAS-IN-47
KRAS-IN-47 is a KRAS inhibitor with IC₅₀ < 50 nM against KRAS G12V. KRAS-IN-47 can be used for the study of cancers .

HY-157029S

KRASG12D-IN-1
KRASG12D-IN-1 (compound 22) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-157031S

KRASG12D-IN-2
KRASG12D-IN-2 (compound 28) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-114436S

MRTX-1257-d6
MRTX-1257-d₆ is the deuterium labeled MRTX-1257 (HY-114436). MRTX-1257 is a selective, irreversible, covalent and orally active KRAS G12C inhibitor, with an IC₅₀ of 900 pM for KRAS dependent ERK phosphorylation in H358 cells .

HY-114277S2

Sotorasib-d3
Sotorasib-d₃ (AMG-510-d₃) is deuterium labeled Sotorasib. Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib leads to the regression of KRAS G12C?mutated locally advanced or metastatic non?small cell lung cancer (NSCLC) .

HY-176358S

*KRAS 2B G12C mutant, Arg-13C6,15N4, Lys-13C6,15N2*
KRAS 2B G12C mutant, Arg- ¹³C₃₆, ¹⁵N₄, Lys- ¹³C₆, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled KRAS 2B G12C mutant.

HY-176359S

*KRAS 2B G12D mutant, Arg-13C6,15N4, Lys-13C6,15N2*
KRAS 2B G12D mutant, Arg- ¹³C₃₆, ¹⁵N₄, Lys- ¹³C₆, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled KRAS 2B G12D mutant.

HY-176354S

*KRAS 2B G12V mutant, Arg-13C6,15N4, Lys-13C6,15N2*
KRAS 2B G12V mutant, Arg- ¹³C₃₆, ¹⁵N₄, Lys- ¹³C₆, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled KRAS 2B G12V mutant.

HY-180885S

*KRAS G12D-IN-35*
KRAS G12D-IN-35 (example 7) is a potent and orally active KRAS G12D inhibitor. KRAS G12D-IN-35 suppresses p-ERK in AGS cells and potently inhibits the proliferation of various KRAS G12D-mutant cancer cell lines. KRAS G12D-IN-35 inhibits tumor growth in HPAC and GP2D mouse models. KRAS G12D-IN-35 can be used for cancer research, such as pancreatic and colorectal cancer .

HY-176357S

*KRAS 2B G12R mutant, Arg-13C6,15N4, Lys-13C6,15N2*
KRAS 2B G12R mutant, Arg- ¹³C₃₆, ¹⁵N₄, Lys- ¹³C₆, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled KRAS 2B G12R mutant.

Host:	Mouse (2)
Reactivity:	Human (2)
Application:	IHC-P (2) FC (2) ELISA (2)
Isotype:	IgG1 (2)
Conjugation:	Non-conjugated (2) Biotin (16)
Clonality:	Monoclonal (1)
Modification:	Unmodified (1)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P84775

	PLA2G12A Antibody (YA4472) GXII; ROSSY; PLA2G12	IHC-P, FC, ELISA	Human
	PLA2G12A Antibody (YA4472) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PLA2G12A.

HY-P84775A

	PLA2G12A Antibody (YA4472)(PBS only) GXII; ROSSY; PLA2G12	IHC-P, FC, ELISA	Human
	PLA2G12A Antibody (YA4472) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PLA2G12A.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-134813

MRTX1133 45+ Cited Publications		Alkynes
MRTX1133 is a noncovalent, potent, and selective alkyne-based KRAS G12D inhibitor. MRTX1133 optimally fills the switch II pocket and extends three substituents to favorably interact with the protein, resulting in an estimated K_D against KRAS G12D of 0.2 pM. MRTX1133 prevents SOS1-catalyzed nucleotide exchange and/or formation of the KRAS G12D/GTP/RAF1 complex, thereby inhibiting mutant KRAS-dependent signal transduction. MRTX1133 selectively inhibits KRAS G12D mutant, but not KRAS wild-type, tumor cells. MRTX1133 has single digit nanomolar activity in cellular assays and marked in vivo efficacy in tumor models harboring KRAS G12D mutations .

HY-173637

AZD0022		Alkynes
AZD0022 is a selective and orally active KRAS ^G12D inhibitor. AZD0022 inhibits KRAS pathway suppression in the GP2D xenograft model .

HY-128522

ARS-1323-alkyne		Alkynes
ARS-1323-alkyne is a covalent inhibitor probe that covalently binds to the Switch-II pocket (S-IIP) of the KRAS G12C mutant protein. ARS-1323-alkyne visualizes the covalent modification of KRAS G12C and quantitatively measures the binding efficiency of the inhibitor to the target. ARS-1323-alkyne can be used to validate the target occupancy of KRAS G12C inhibitors and the synergistic mechanism of combination therapy .

HY-176786

MCB-36		Alkynes
MCB-36 is a VHL-recruiting pan-KRAS PROTAC degrader without affecting KRAS transcription. MCB-36 exhibits minimal effects on HRAS and NRAS protein levels. MCB-36 binds to the GDP-loaded state of G12D, G12C, G12V, and wild-type KRAS with high affinities K_d ≈ 1 pM). MCB-36 decreases p-ERK levels, leading to cell apoptosis. MCB-36 effectively suppress KRAS ^G12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-36 can be used for the study of colorectal cancer and lung cancer (Pink: Target protein ligand; Blue: E3 ligand (HY-112078); Black: Linker (HY-W091879)) .

HY-159652

KRAS inhibitor-31 1 Publications Verification		Alkynes
KRAS inhibitor-31 (compound 33) is a KRAS inhibitor, with K_D (SPR) values of 0.019 nM, 0.019 nM and 0.096 nM for KRas G12D, KRas G12C and KRas G12V, respectively .

HY-176785S

MCB-294		Alkynes
MCB-294 is a dual-state pan-KRAS inhibitor that selectively inhibits KRAS over NRAS and HRAS. MCB-294 capable of binding both the active (GTP-bound) and inactive (GDP-bound) forms of KRAS with K_ds of approximately 1 pM and 10 nM, respectively. MCB-294 broadly impairs the growth of hTERT-HPNE cells expressing G12D, G12C, G12V, G12S, G13D, and wild-type KRAS, with IC₅₀s of approximately 700 nM. MCB-294 induces irreversible apoptosis in KRAS-mutated tumors. MCB-294 effectively suppress KRAS ^G12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-294 can be used for the study of pancreatic cancer, colorectal cancer and lung cancer .

HY-179253

KRAS-IN-47		Alkynes
KRAS-IN-47 is a KRAS inhibitor with IC₅₀ < 50 nM against KRAS G12V. KRAS-IN-47 can be used for the study of cancers .

HY-134654

MRTX849 analog 24		Alkynes
MRTX849 analog 24 is an alkyne-containing click probe analogue of KRAS G12C inhibitor MRTX849, which is used to research MRTX849 function .

HY-115880A

*KRAS G12D inhibitor 3 TFA*		Alkynes
KRAS G12D inhibitor 3 TFA is a KRAS G12D inhibitor with an IC₅₀ of <500 nM. KRAS G12D inhibitor 3 TFA has antitumor effects (WO2022002102A1; compound 146) . KRAS G12D inhibitor 3 (TFA) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-159474

KRAS inhibitor-24		Azide
KRAS inhibitor-24 (compound 115c) is a pyridopyrimidine KRAS inhibitor, with an IC₅₀ of < 100 nM for KRas G12V, KRas WT and KRas G12R .

HY-145962A

MRTX-EX185 formic		Alkynes
MRTX-EX185 formic is a potent KRAS (G12D) inhibitor with an IC₅₀ of 90 nM. MRTX-EX185 formic can binds both GDP-loaded and active GNP states of KRAS and KRAS (G12D). MRTX-EX185 formic exhibits broad-spectrum binding properties with IC₅₀s of 110, 290, 130 and 240 nM for KRAS WT, KRAS (G12C), KRAS (Q61H), KRAS (G13D). MRTX-EX185 formic also binds GDP-loaded HRAS. MRTX-EX185 formic can be used to study various RAS-driven tumors (such as pancreatic cancer) .

HY-157029S

KRASG12D-IN-1		Alkynes
KRASG12D-IN-1 (compound 22) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-157031S

KRASG12D-IN-2		Alkynes
KRASG12D-IN-2 (compound 28) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-134811

*KRAS G12D inhibitor 1*		Alkynes
KRAS G12D inhibitor 1 is a KRAS ^G12D inhibitor with an IC₅₀ value of 0.4 nM. KRAS G12D inhibitor 1 inhibits KRas ^G12D-mediated ERK phosphorylation. KRAS G12D inhibitor 1 can be used for cancer research .

HY-115880

*KRAS G12D inhibitor 3*		Alkynes
KRAS G12D inhibitor 3 is a KRAS G12D inhibitor with an IC₅₀ of <500 nM. KRAS G12D inhibitor 3 has antitumor effects (WO2022002102A1; compound 146) . KRAS G12D inhibitor 3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-147595

*KRAS G12D inhibitor 15*		Alkynes
KRAS G12D inhibitor 15 is a potent inhibitor of KRAS G12D. KRAS G12D inhibitor 15 has the potential for the research of various diseases or disorders, such as cancer or cancer metastasis (extracted from patent WO2022042630A1, compound 243) . KRAS G12D inhibitor 15 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-175860

*KRAS G12D ligand-Linker Conjugate 2*		Alkynes
KRAS G12D ligand-Linker Conjugate 2 is a conjugate of the KRAS (G12D) ligand (HY-175859) and the linker (HY-168698). KRAS G12D ligand-Linker Conjugate 2 can be used for synthesizing PROTAC KRAS (G12D) degrader ASP-3082 (HY-157505) .

HY-179403

KRASG12C IN-17		Alkynes
KRASG12C IN-17 is an orally active covalent KRAS ^G12C inhibitor, showing strong inhibitory activity in KRAS ^G12C-mutant cancer cells (NCI-H23 IC₅₀ = 0.7 nM; NCI-H358 IC₅₀ = 0.5 nM). KRASG12C IN-17 covalently and irreversibly binds to KRAS ^G12C with > 96% modification efficiency in both GDP-bound and GMPPNP-bound conformations. KRASG12C IN-17 can be used for studies of KRAS-driven cancers, including colorectal cancer .

HY-179300A

KRAS-IN-48		Alkynes
KRAS-IN-48 (Compound 1-01) is a KRAS mutant inhibitor, with K_d values of 2.58 nM and 5.49 μM for KRAS-G12D and KRAS-G12V, respectively. KRAS-IN-48 can be used in the research of cancer .

HY-145962

MRTX-EX185		Alkynes
MRTX-EX185 is a potent KRAS (G12D) inhibitor with an IC₅₀ of 90 nM. MRTX-EX185 can binds both GDP-loaded and active GNP states of KRAS and KRAS (G12D). MRTX-EX185 exhibits broad-spectrum binding properties with IC₅₀s of 110, 290, 130 and 240 nM for KRAS WT, KRAS (G12C), KRAS (Q61H), KRAS (G13D). MRTX-EX185 also binds GDP-loaded HRAS. MRTX-EX185 can be used to study various RAS-driven tumors (such as pancreatic cancer) .

HY-159476

KRAS inhibitor-26		Azide
KRAS inhibitor-26 (compound 194a) is a potent KRAS G12V inhibitor (IC₅₀: ≤100 nM). KRAS inhibitor-26 can be used for cancer research .

HY-158007

*(RS)-G12Di-1*		Alkynes
(RS)-G12Di-1 is a selective, covalent inhibitor of *K-Ras-G12D* .

HY-158701

*KRAS G12D inhibitor 23*		Alkynes
KRAS G12D inhibitor 23 (compound 46-3) is a potent inhibitor of KRAS G12D, with the IC₅₀ of 0.007 μM. KRAS G12D inhibitor 23 plays an important role in cancer research .

HY-176870

KRAS-IN-42		Alkynes
KRAS-IN-42 (Compound Z1063) is a covalent KRAS ^G12D mutants inhibitor. KRAS-IN-42 is promising for research of KRAS ^G12D-mutant cancers (e.g., non-small cell lung cancer, colorectal cancer) .

HY-162446

pan-KRAS-IN-13		Alkynes
pan-KRAS-IN-13 (compound 2) is a potent inhibitor of KRAS, with IC₅₀s of 2.75 nM and 2.89 nM for G12D and G12V, respectively

HY-163488

KRASG12D-IN-4		Alkynes
KRASG12D-IN-4 (example 38) is a KRas ^G12D inhibitor with an IC₅₀ of 3.3 nM. KRASG12D-IN-4 inhibits proliferation of pancreatic cancer ASPC-1 cells with an IC₅₀ of 12 nM .

HY-159475

KRAS inhibitor-25		Azide
KRAS inhibitor-25 (compound 151a) is a pyridopyrimidine KRAS inhibitor, with an IC₅₀ of < 100 nM against KRas G12V, KRas WT and KRas G12R .

HY-159473

K-Ras-IN-3		Alkynes
K-Ras-IN-3 (compound 3) is a potent GDP-KRAS G12V inhibitor with an IC₅₀ value of 0.371 nM. K-Ras-IN-3 has the potential for the research of cancer .

HY-180920

*KRAS G12D-IN-36*		Alkynes
KRAS G12D-IN-36 (Compound 53a) is a highly selective and orally active *KRAS-G12D* inhibitor with an IC₅₀ of 1.63 nM. KRAS G12D-IN-36 effectively inhibits p-ERK with an IC₅₀ of 8.4 nM. KRAS G12D-IN-36 shows potent anti-proliferative activity against AsPC-1 cells. KRAS G12D-IN-36 can be used for research on pancreatic cancer .

HY-179404

KRASG12C IN-18		Alkynes
KRASG12C IN-18 is an orally active covalent KRAS ^G12C inhibitor that achieves complete covalent engagement of KRAS ^G12C in both GDP- and GMPPNP-bound states and displays strong antiproliferative activity against KRAS ^G12C and resistance-associated variants, including KRAS ^G12C/R68S, with low-nanomolar IC₅₀ values. KRASG12C IN-18 exhibits marked in vivo efficacy in KRAS ^G12C-driven solid tumor and KRAS ^G12C/R68S xenograft models and can be used for colorectal cancer research .

HY-179300

KRAS-IN-48 free base		Alkynes
KRAS-IN-48 free base (Compound 1-01) is a mutant KRAS inhibitor, with K_d values of 2.58 nM and 5.49 μM for KRAS G12D and KRAS G12V, respectively. KRAS-IN-48 free base affects pERK expression in cells harboring KRAS G12D and KRAS G12V mutations, with IC₅₀ values of 1.1 μM and 1.51 μM, respectively. KRAS-IN-48 free base can be used in the research of cancer .

Cat. No.	Product Name		Classification

HY-111648

6-O-Methyl Guanosine		Nucleoside Analogs Guanosine
6-O-Methyl Guanosine is a Ribonucleoside. Replacement of the conserved G5, G8 or G12 residues in hammerhead ribozymes with 6-O-Methyl Guanosine reduces k_cat without altering K_m. 6-O-Methyl Guanosine exerts position-dependent regulatory effects on ribosomal velocity and fidelity. When 6-O-Methyl Guanosine is located at the first or third position of a codon, it decreases the accuracy of tRNA selection. When 6-O-Methyl Guanosine is located at the second position of a codon, it slows down the peptide bond formation rate of cognate aminoacyl-tRNA but does not change the reaction rate of near-cognate aminoacyl-tRNA .

HY-RS10617

PLA2G12A Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
PLA2G12A Human Pre-designed siRNA Set A contains three designed siRNAs for PLA2G12A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10618

PLA2G12B Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
PLA2G12B Human Pre-designed siRNA Set A contains three designed siRNAs for PLA2G12B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS26054

Pla2g12b Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Pla2g12b Rat Pre-designed siRNA Set A contains three designed siRNAs for Pla2g12b gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS19558

Pla2g12b Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Pla2g12b Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pla2g12b gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks